The impact of venetoclax based regimens in the preemptive of measurable residual disease in acute myeloid leukemia  

作　　者：Qiuyun Fang Xiaoyuan Gong Yan Li Benfa Gong Yuntao Liu Kaiqi Liu Guangji Zhang Shuning Wei Dong Lin Bingcheng Liu Ying Wang Hui Wei Yingchang Mi Jianxiang Wang 

机构地区：[1]State Key Laboratory of Experimental Hematology,National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem,Institute of Hematology&Blood Diseases Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,No.288 Nanjing Road,Tianjin,China

出　　处：《Blood Science》2022年第1期44-46,共3页血液科学（英文）

基　　金：funded by Tianjin Clinical Research Center:Construction of Tianjin Clinical Research Center for Blood Diseases(2016.4-2019.12)(15ZXLCSY00010);National Key Research and Development Program of China(2021YFC2500003).

摘　　要：To The Editor:The role of measurable residual disease(MRD)in prognosis and treatment in acute myeloid leukemia(AML)is evolving.Studies have demonstrated the correlation between MRD and risks of relapse in adult AML:persistently positive MRD after induction is associated with a high risk of relapse,1,2 and these patients should consider allogeneic transplantation(allo-Hematopoietic Stem Cell Transplantation(HSCT))and clinical trial,even in favorable-risk groups.However,because of the financial issue or lack of suitable transplant donors,many of the patients could not receive allo-HSCT,so how to prolong the relapse-free survival of these patients remains a challenge.Platzbecker et al treated MRD-positive patients with azacytidine(AZA),and found pre-emptive therapy with AZA can prevent or substantially delay hematological relapse in MRD-positive patients with MDS(myelodysplastic syndrome)or AML who are at a high risk of relapse.

关 键 词：MYELOID ACUTE REGIMEN 

分 类 号：R73[医药卫生—肿瘤]